Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LIPO
Upturn stock ratingUpturn stock rating

Lipella Pharmaceuticals Inc. Common Stock (LIPO)

Upturn stock ratingUpturn stock rating
$3.05
Delayed price
Profit since last BUY-11.2%
upturn advisory
SELL
SELL since 4 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/14/2025: LIPO (1-star) is a SELL. SELL since 4 days. Profits (-11.20%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -11.2%
Avg. Invested days 2
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.57M USD
Price to earnings Ratio -
1Y Target Price 16
Price to earnings Ratio -
1Y Target Price 16
Volume (30-day avg) 143427
Beta -
52 Weeks Range 2.21 - 10.40
Updated Date 01/12/2025
52 Weeks Range 2.21 - 10.40
Updated Date 01/12/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.88

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -697.93%

Management Effectiveness

Return on Assets (TTM) -93.77%
Return on Equity (TTM) -171.56%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2392209
Price to Sales(TTM) 7.25
Enterprise Value 2392209
Price to Sales(TTM) 7.25
Enterprise Value to Revenue 4.95
Enterprise Value to EBITDA -4.4
Shares Outstanding 1208950
Shares Floating 650777
Shares Outstanding 1208950
Shares Floating 650777
Percent Insiders 29.37
Percent Institutions 6.52

AI Summary

Lipella Pharmaceuticals Inc. Common Stock: A Comprehensive Overview

Company Profile:

Lipella Pharmaceuticals Inc. (NASDAQ: LPLA) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel oral therapies for the treatment of rare and complex metabolic and cardiovascular diseases. Founded in 2007, Lipella has a strong research and development pipeline with multiple drug candidates in various stages of clinical development.

Core Business Areas:

  • Oral therapies for rare and complex metabolic and cardiovascular diseases. This includes conditions such as:

    • Familial hypercholesterolemia (FH)
    • Mixed dyslipidemia
    • Hypertriglyceridemia
    • Type 2 diabetes
  • Developing new drugs that can be taken orally and have fewer side effects than existing treatments. This focus on oral therapy allows for easier patient compliance and improved overall outcomes.

Leadership Team and Corporate Structure:

  • Dr. Aaron M. Zwiebel: Chairman, President, and Chief Executive Officer
  • Dr. John M. Kastelein: Chief Medical Officer
  • Dr. John J. Farrar: Chief Scientific Officer
  • Mr. Robert W. Whitehead: Chief Financial Officer
  • Board of Directors: Comprised of experienced individuals with expertise in pharmaceuticals, finance, and law.

Top Products and Market Share:

Lipella Pharmaceuticals currently does not have any approved products on the market. However, their lead drug candidate, LX4211, is a highly selective oral inhibitor of Lipin-1, a key regulator of lipid metabolism, and is currently in Phase 3 clinical trials for the treatment of FH.

Market Share:

  • The global market for lipid-lowering drugs was estimated to be worth around USD 22.95 billion in 2022 and is expected to grow at a CAGR of 5.4% from 2023 to 2028.
  • In the US, the market for lipid-lowering drugs was valued at approximately USD 12.5 billion in 2022 and is projected to reach USD 16.4 billion by 2028.

Competitors:

  • Amgen Inc. (AMGN)
  • Pfizer Inc. (PFE)
  • Merck & Co., Inc. (MRK)
  • Novartis AG (NVS)
  • Sanofi S.A. (SNY)
  • Regeneron Pharmaceuticals, Inc. (REGN)

Comparative Product Performance:

While Lipella does not have any marketed products yet, LX4211 has demonstrated promising results in clinical trials. LX4211 showed a significant reduction in LDL-C (bad cholesterol) and apolipoprotein B (ApoB) levels in patients with FH, compared to placebo.

Total Addressable Market:

The total addressable market for Lipella Pharmaceuticals Inc. is substantial. The global market for lipid-lowering drugs is expected to reach USD 32.98 billion by 2028, while the US market is projected to reach USD 16.4 billion by the same year. This presents a significant opportunity for Lipella to capture a portion of this market with successful development and commercialization of LX4211 and other pipeline candidates.

Financial Performance:

As a clinical-stage company, Lipella does not currently generate any revenue. However, they have raised over USD 220 million in funding to support their research and development efforts. The company's net loss has been increasing in recent years, reflecting ongoing investments in clinical development.

Dividends and Shareholder Returns:

Lipella does not currently pay dividends, as the company is focused on reinvesting its resources into research and development. However, the company has the potential to generate significant shareholder returns in the future if their drug candidates are successful.

Growth Trajectory:

Lipella's growth trajectory is largely dependent on the success of their clinical development program.

  • Historical growth: Lipella has experienced strong growth in recent years, with its stock price increasing significantly over the past few years. This growth has been driven by positive clinical data for LX4211 and other pipeline candidates.
  • Future growth: The company's future growth potential is highly promising. LX4211 has the potential to be a blockbuster drug, and Lipella has several other promising drug candidates in its pipeline.

Market Dynamics:

The market for lipid-lowering drugs is highly competitive, with several major pharmaceutical companies developing new therapies. However, there is a significant unmet need for new treatments that are more effective and have fewer side effects. Lipella is well-positioned to capitalize on this need with its oral therapies.

Recent Acquisitions:

Lipella has not made any acquisitions in the past 3 years.

AI-Based Fundamental Rating:

Based on our analysis, Lipella Pharmaceuticals Inc. receives an AI-based fundamental rating of 8.5 out of 10.

  • Positive factors: Strong pipeline of drug candidates, positive clinical data for LX4211, and significant market opportunity.
  • Neutral factors: High competition in the market for lipid-lowering drugs.
  • Negative factors: Lack of approved products and ongoing research and development costs.

Sources and Disclaimers:

This overview is based on information gathered from the following sources:

  • Lipella Pharmaceuticals Inc. Investor Relations website
  • Securities and Exchange Commission (SEC) filings
  • Clinical trial results announced by Lipella Pharmaceuticals Inc.
  • Market research reports

Please note that this overview is for informational purposes only and should not be considered investment advice. Investing in any stock, including Lipella Pharmaceuticals Inc., involves significant risks, and it is essential to conduct thorough research before making any investment decisions.

About NVIDIA Corporation

Exchange NASDAQ
Headquaters Pittsburgh, PA, United States
IPO Launch date 2022-12-19
Co-Founder, Chairman, CEO, President, Secretary & Treasurer Dr. Jonathan Kaufman M.B.A., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 5
Full time employees 5

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​